āļ¸āˇāļŊ⎠āļ´āˇāļ§āˇāˇAZN âĸ LON
add
AstraZeneca plc
āļāˇāļGB āˇāˇāļģāˇāļāˇāļ¸ āļŊāˇāļēāˇāˇāˇāļāˇāļāļ āļāļģ āļāļGB āļ¸āˇāļŊāˇāˇāļŽāˇāļąāļē āˇāˇ
āļ´āˇāļģ āˇāˇāˇāˇāļ¸
GBXÂ 11,036.00
āļ¯āˇāļą āļ´āļģāˇāˇāļē
GBXÂ 10,994.00 - GBXÂ 11,102.00
āˇāˇāļģ āļ´āļģāˇāˇāļē
GBXÂ 9,573.50 - GBXÂ 13,388.00
āˇāˇāˇ
āļŗāļ´āˇāˇ
āļ´āˇâāļģāˇāļāˇāļ°āļąāļē
āļļāˇ234.12 USD
āˇāˇāļ¸āˇāļąāˇâāļēāļē āļ´āļģāˇāļ¸āˇāˇ
āļ¸āˇ2.46
P/E āļ
āļąāˇāļ´āˇāļāļē
27.99
āļ´āˇâāļģāļāˇāļŊāˇāļˇāļē⎠āļŊāˇāļˇāˇāļāˇāļē
2.21%
āļ¸āˇāļŊāˇāļ āˇāˇāˇāļ¸āˇāļģāˇāˇ
LON
āļ´āˇāˇāļ⎠āļāˇāˇ
āļ¸āˇāļŊāˇâāļē
āļāļ¯āˇāļēāļ¸āˇ āļ´āˇâāļģāļāˇāˇāļē
āļāļ¯āˇāļēāļ¸
āˇāˇāļ¯āˇāļ° āļāļ¯āˇāļēāļ¸
(USD) | 2025 āļĸāˇāļąāˇinfo | āˇ/⎠āˇāˇāļąāˇ |
---|---|---|
āļāļ¯āˇāļēāļ¸ | āļļāˇ14.46 | 11.74% |
āļ¸āˇāˇāˇāļēāˇāļ¸āˇ āˇāˇāļēāļ¯āļ¸ | āļļāˇ8.42 | 5.12% |
āˇāˇāļ¯āˇāļ° āļāļ¯āˇāļēāļ¸ | āļļāˇ2.45 | 27.14% |
āˇāˇāļ¯āˇāļ° āļŊāˇāļˇ āļāļąāˇāļāˇāļāļē | 16.95 | 13.83% |
āļāˇāļ§āˇāļāļ§ āļāļ´āˇāļēāˇāļ¸āˇ | 2.17 | 119.19% |
EBITDA | āļļāˇ4.88 | 21.14% |
āļļāļŊāˇāļāˇāļ¸āļ āļļāļ¯āˇ āļ
āļąāˇāļ´āˇāļāļē | 21.71% | â |
āˇāˇāˇ āļ´āļāˇâāļģāļē
āļ¸āˇāˇ
⎠āˇāļāˇāļāļ¸āˇ
āļ¸āˇāˇ
⎠āˇāļāļāˇāļ¸āˇ
(USD) | 2025 āļĸāˇāļąāˇinfo | āˇ/⎠āˇāˇāļąāˇ |
---|---|---|
āļ¸āˇāļ¯āļŊ⎠āˇāˇ āļāˇāļ§āˇ āļāˇāļŊāˇāļą āļāļēāˇāļĸāļą | āļļāˇ7.11 | 0.45% |
āļ¸āˇāˇ
⎠āˇāļāˇāļāļ¸āˇ | āļļāˇ112.42 | 7.75% |
āļ¸āˇāˇ
⎠āˇāļāļāˇāļ¸āˇ | āļļāˇ67.61 | 4.43% |
āļ¸āˇāˇ
⎠āˇāļ¸āļāˇāļ§āˇāˇ | āļļāˇ44.81 | â |
āˇāˇāļ āļāˇāļ§āˇāˇ | āļļāˇ1.55 | â |
āˇāˇāļąāˇ āļāļģāˇāˇ āļāˇāļąāˇāļ¸āļ§ āļ¸āˇāļŊ | 3.83 | â |
āˇāļāˇāļāļ¸āˇāˇāļŊ āļ´āˇâāļģāļāˇāļŊāˇāļˇ | 7.97% | â |
āļ´āˇâāļģāˇāļāˇāļ°āļąāļē āļ¸āļ āļ´āˇâāļģāļāˇāļŊāˇāļˇ | 11.58% | â |
āļ¸āˇāļ¯āļŊ⎠āļ´āˇâāļģāˇāˇāˇāļē
āļ¸āˇāļ¯āļŊāˇāˇāļŊ āˇāˇāļ¯āˇāļ° āˇāˇāļąāˇ
(USD) | 2025 āļĸāˇāļąāˇinfo | āˇ/⎠āˇāˇāļąāˇ |
---|---|---|
āˇāˇāļ¯āˇāļ° āļāļ¯āˇāļēāļ¸ | āļļāˇ2.45 | 27.14% |
āļ¸āˇāˇāˇāļēāˇāļ¸āˇāˇāļŊāˇāļąāˇ āļ¸āˇāļ¯āļŊ⎠| āļļāˇ3.39 | 9.76% |
āļāļēāˇāļĸāļąāļēāˇāļąāˇ āļ¸āˇāļ¯āļŊ⎠| -āļļāˇ2.11 | 26.60% |
āļ¸āˇāļŊāˇâāļēāļāļģāļĢāļēāˇāļąāˇ āļ¸āˇāļ¯āļŊ⎠| āļ¸āˇ518.00 | 142.39% |
āļ¸āˇāļ¯āļŊāˇāˇāļŊ āˇāˇāļ¯āˇāļ° āˇāˇāļąāˇ | āļļāˇ1.82 | 279.80% |
āļąāˇāļ¯āˇāˇāˇ āļ¸āˇāļ¯āļŊ⎠āļ´āˇâāļģāˇāˇāˇāļē | āļļāˇ1.61 | -19.07% |
āļ´āˇāˇ
āˇāļļāļŗ
AstraZeneca plc is a British-Swedish multinational pharmaceutical and biotechnology company with its headquarters at the Cambridge Biomedical Campus in Cambridge, UK. It has a portfolio of products for major diseases in areas including oncology, cardiovascular, gastrointestinal, infection, neuroscience, respiratory, and inflammation.
The company was founded in 1999 through the merger of the Swedish Astra AB and the British Zeneca Group. Its portfolio includes primary and speciality care, coverage for rare diseases, and a robust global presence across various regions. Since the merger it has been among the world's largest pharmaceutical companies and has made numerous corporate acquisitions, including Cambridge Antibody Technology, MedImmune, Spirogen and Definiens. It has its research and development concentrated in three strategic centres: Cambridge, UK; Gothenburg, Sweden; and Gaithersburg, Maryland, US.
AstraZeneca traces its earliest corporate history to 1913, when Astra AB was formed by a large group of doctors and apothecaries in SÃļdertälje. Throughout the twentieth century, it grew into the largest pharmaceutical company in Sweden. Wikipedia
āļ¸āˇāļŊāˇāˇāļŽāˇāļąāļē
1999 āļ
āļ´āˇâāļģāˇāļŊ⎠6
āļ¸āˇāļŊāˇāˇāļŽāˇāļąāļē
āˇāˇāļļ⎠āļ
āļŠāˇāˇāļē
āˇāˇāˇāļāļēāˇāļąāˇ
94,300